Fisher Scientific said this week that it agreed to acquire Dharmacon for $80 million in cash, putting to rest rumors circulating throughout the industry that the privately held RNA reagent provider was on the block.
Fisher said that acquiring Dharmacon — which generated about $17 million in revenues last year — will help expand the company’s presence in the life sciences market, and is expected to help boost sales of higher-margin, proprietary products.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
